Jemperli was the first drug in the class to be approved for front-line use in endometrial cancer last year, based on progression-free survival data from RUBY, but with a restricted label that ...

Jemperli – the seventh approved drug in the PD-1/PD-L1 inhibitor class – was acquired by GSK as part of its $5.1 billion takeover of Tesaro along with PARP inhibitor Zejula (niraparib ...